Acta Entomology and Zoology

E-ISSN: 2708-0021
P-ISSN: 2708-0013
Impact Factor (RJIF): 5.83
www.actajournal.com
AEZ 2025; 6(2): 259-262
Received: 15-07-2025
Accepted: 21-08-2025

Estabraq Hassan Badder Al-Muhanna
Jabir ibn Hayyan University for Medical and Pharmaceutical Science Faculty of Medicine Science

Haider Haleem Aljadooa
Department of Medical Laboratories Techniques, College of Health and Medical Techniques, AL-Mustaqbal University, Hilla, Babylon State, Nader Street, 51001, IRAQ

Haider Hamzah Al-Shreefy
Laboratories Techniques Department, College of Health and Medical Techniques, AL-Mustaqbal University, 51001, Babylon Iraq

Noor-Aldeen Adhem
Laboratories Techniques Department, College of Health and Medical Techniques, AL-Mustaqbal University, 51001, Babylon Iraq

Rasha Saad Toma
Ph.D. biology/microbiology, Department of Medical Lab Technique, Imam Jaafar Al-Sadiq University, IRAQ.

Ghadeer Sabah Bustani
Department of Medical Laboratory Technology, College of Medical Technology, The Islamic University, Najaf, Iraq.

Baraa Akeel Al-Hasan
a) Department of Medical Laboratory Technology, College of Medical Technology, the Islamic University, Najaf, Iraq
b) Department of Laboratory, Al Najaf Veterinary Hospital, Najaf, Iraq
c) Department of Veterinary Microbiology, College of Veterinary Medicine, University of Al-Qadisiyah, Diwaniyah City, Iraq

Dhuhah Hayder Abdul-Jawad
Ph.D. Biology/Microbiology/Virology Faculty of Medicine, University of Kufa-Iraq

Mohammed Qasim Salih Mahdi
Department of Pathological Analysis, Faculty of Science, University of Kufa, Kufa, Iraq

Corresponding Author:
Haider Haleem Aljadooa
Department of Medical Laboratories Techniques, College of Health and Medical Techniques, AL-Mustaqbal University, Hilla, Babylon State, Nader Street, 51001, Iraq

Examining *Escherichia coli*'s genetic variability: Consequences for pathophysiology and antimicrobial resistance (*E. coli* genetic diversity: Pathophysiology & resistance)

Estabraq Hassan Badder Al-Muhanna, Haider Haleem Aljadooa, Haider Hamzah Al-Shreefy, Noor-Aldeen Adhem, Rasha Saad Toma, Ghadeer Sabah Bustani, Baraa Akeel Al-Hasan, Dhuhah Hayder Abdul-Jawad and Mohammed Qasim Salih Mahdi

DOI: https://www.doi.org/10.33545/27080013.2025.v6.i2d.260

Abstract
Background: Urinary tract infections and bacillary dysentery are among the many illnesses that people and animals can get from the varied bacterial species *Escherichia coli*. Its pathogenic potential is enhanced by the presence of virulence factors and genes resistant to antibiotics in its genome. Mobile genetic elements like plasmids, which promote the horizontal transmission of virulence and resistance characteristics, have an impact on these genes. Its genetic diversity is further shaped by environmental factors, such as interactions within biotic and abiotic niches.
Objectives: With an emphasis on pathogenicity, population structure, and the consequences for antibiotic resistance, this research attempts to investigate the genetic diversity of *Escherichia coli*. According to genetic study, microbial interactions and environmental factors influence population formations. Meningitis-causing strains and ExPEC are examples of subgroups that display unique genetic lineages that reflect host and niche adaptability. One of the main forces behind genetic variety is horizontal gene transfer, which makes it possible for features that improve pathogenicity and survival to be acquired quickly.
Results: The findings show that *E. coli*'s genetic variety is essential to its capacity for adaptation and evolution. New strains with distinct resistance and virulence traits evolve as a result of the interaction between genetic variation and environmental variables. Nevertheless, this diversity's functional characterisation is still lacking, requiring more investigation.
Conclusion: In conclusion, creating efficient plans to fight illnesses and lessen the worldwide burden of antibiotic resistance requires a knowledge of the genetic variety and population dynamics of *E. coli*. To meet the problems presented by this versatile and more resistant virus, increased monitoring, molecular typing, and cooperative research are essential.

Keywords: *E. coli*, genetic, antimicrobial

1. Introduction
Escherichia coli strains that have genes for antibiotic resistance cause a variety of illnesses in both people and animals. Bacillary dysentery and urinary tract infections may result from them [4]. The genomes of pathogens, such as *E. coli*, are varied and contain resistance genes and virulence factors. Comprehending these genes is essential to comprehending their pathogenic benefits [20, 6]. *E. coli* is common in people and is frequently detected in sewage and the stomach. It can lead to illnesses and food contamination. It spreads through livestock facilities and chickens. The bacteria *E. coli* is harmful and resistant to antibiotics [18].

2. Genetic Diversity of *Escherichia coli*
Mobile genetic elements are responsible for the wide genetic variety found in *Escherichia coli*. Plasmids aid in transmission and encode new factors. Independent of plasmids, genetic diversity in the core genome affects pathogenicity and host adaptability as well. Although this diversity's functional characterisation is lacking, it is essential to the adaptability and development of *E. coli*. Concerns are raised regarding the factors influencing *E. coli*'s genetic makeup [12].

By favoring particular characteristics, environmental stresses mold the genetic diversity of bacteria. Genetic diversity is impacted by interactions between *E. coli* populations and their surroundings. Both biotic and abiotic niche variables affect bacterial populations. Not all of the virulence factors that *E. coli* populations display are harmful [7, 15].

2.1. Population Structure

Genetic analysis of *Escherichia coli* reveals relationships, transmission dynamics, and strain differences. Population structure differs based on sub-structuring, including ExPEC and meningitis strains. Environmental conditions and microbial influences drive diversity. Understanding dynamics allows comprehension of population structure [1].

Individuals colonized by bacterial pathogens carry multiple clonal and genetic lineages. New strains replace others. Extraintestinal *E. coli* show a clonal structure with implications for transmission dynamics. The population structure is sub-structured, with a few individuals carrying clones responsible for symptoms. Pathogenicity can be acquired through virulence genes or changes in gene expression, or by hybridizing commensal and pathogenic lineages. Acquisition events occur horizontally. Understanding *E. coli*'s population structure is important for managing diseases caused by this species, including controlling strains, interrupting transmission, and understanding pathogenic steps. This review summarizes genetic and pathogenic diversity in *E. coli.* [5]

2.2. Horizontal Gene Transfer

One important route for genetic variety in *E. coli* populations is horizontal gene transfer, or HGT. HGT is the process by which bacteria, primarily, acquire genes from other species. Among the mechanisms are conjugation (direct cell-cell DNA transfer via plasmids), transduction (transmission via bacteriophages), and transformation (uptake of bare DNA) [21, 23].

Gut viruses spread virulent factors among bacteria, preventing rivals and predators from growing. There are important ramifications for evolution, health, food safety, and medicine. Because of some genes and their quick proliferation, virulence factor acquisition and resistance are difficult to characterize. By facilitating the movement of genetic material, horizontal gene transfer (HGT) helps pathogens adapt to different growing locales [10].

3. Pathogenicity Mechanisms

There are intestinal and enteropathogenic strains of *E. coli* that are harmful to people, animals, and birds. Although virulence factors have been discovered in the intestines of infected animals, it is difficult to detect them in people. After first colonizing the gut, *E. coli* moves to other areas of the body, where it kills host cells and eludes the immune system. Pathogenic strains live inside host cells for protection and release virulence proteins through the type III secretion system. During epidemics, whole genome sequencing can identify novel virulence factors, enhancing diagnosis and controlling the disease. Proteomic analysis and identification based on peptide sequencing are novel methods for researching *E. coli*. Species and strains are identified using molecular microbiology, immunobiochemistry, and 16S rRNA sequencing. Whole-cell subproteomes may be thoroughly identified to enable proteogenomic analysis [22].

4. Antimicrobial Resistance in *Escherichia coli*

With grave consequences for public health across the world, AMR *E. coli* is a global health problem. Because there are few viable treatment options, the growth in these illnesses poses serious dangers and expenses. Sadly, a lot of these illnesses have become resistant to medicines, making effective treatment difficult [17]. The existence of healthy carriers is a significant element in the propagation of AMR *E. coli*. These carriers increase the frequency of illnesses by unintentionally harboring and spreading the germs. To stop the spread of this antibiotic-resistant strain, the problem of healthy carriers must be addressed [9] Furthermore, it is impossible to overestimate the significance of genetic diversity in the development of AMR. The *E. coli* strain's genetic changes have a significant impact on its capacity to develop antibiotic resistance, which enables it to change and adapt to different treatment modalities. In order to effectively address AMR and lessen its influence on global health, it is crucial to comprehend these genetic pathways [16].

In conclusion, considering the scarcity of available treatments and the existence of healthy carriers, AMR *E. coli* represents a serious threat to world health. The development of this strain is significantly influenced by the interaction between antibiotic resistance and genetic diversity. Prioritizing research, surveillance, and the creation of creative tactics to fight AMR and safeguard public health are essential in order to solve this urgent problem [14, 24].

Antimicrobials and resistant genes are involved in the spread of resistance in *E. coli*. It is a worldwide issue that impacts different antibiotics. Plasmids and efflux systems are the primary causes of multidrug resistance. Varied kinds of β-lactamase enzymes have varied ways of surviving antibiotics [2, 25].

4.1. Mechanisms of Resistance

E. coli will naturally be resistant to some antibacterial agents due to intrinsic resistances, which are constitutive and not the result of acquired genetic factors. Factors causing intrinsic resistance include low outer membrane permeability, the presence of actively effluxing multi-component transport proteins, and a high copy number of target enzymes that aid in the breakdown of β-lactam antibiotics. Other mechanisms by which *E. coli* acquires resistance include the transmission of resistance genes carried by plasmids and other mobile genetic elements, the fixation of mutations in chromosomal genes, and the acquisition of genes by horizontal gene transfer, all of which facilitate phenotypic resistance [3].

Numerous mechanisms exist by which *E. coli* demonstrates antimicrobial resistance. Two main types of resistance can be identified: intrinsic, resulting from an inherent quality (i.e., lack of porins), and acquired, which results from the acquisition of a gene via mobile genetic elements. Antimicrobial resistance of pathogens causes treatment regimens to fail, resulting in increased healthcare costs and patient mortality [13]. Resistance mechanisms of *E. coli* can be intrinsic, acquired, or result from environmental influences. Resistance may be due to enzymatic inactivation of the antibacterial agent, such as modification of target enzymes, or degradation of the antibiotic by enzymatic digestion, such as β-lactam antibiotics. It may also be the result of urgent removal of the antibiotic from target sites by

changes in the membrane or removal of unwanted chemicals through active efflux, which is especially prevalent in tetracycline resistance. Understanding how antimicrobial resistance can develop, or is obtained and used by *E. coli* to induce disease, will develop new, innovative strategies to stop outbreaks and diminish the effects of antimicrobial resistance [11].

4.2. Epidemiology and Surveillance

A specific *E. coli* phenotype in a location may reflect local factors, with no plague or SPLA strains until investigated. Older research shows increasing percentages of resistant strains in worldwide hospitals. Endemic trends reflect specific populations, presented as figures at different scales. Evaluations collected nationwide fecal samples, reporting AMR patterns in humans and animals due to medical and veterinary antimicrobial use [19].

The prevalence of resistant *E. coli* strains, indicative of their scrutiny in primary care settings, may be overshadowed by other normal flora. The BOX sequence profile of NCTC 86 experienced changes during passaging, but it's unclear if this affected all cell lines. Researchers aim to find connections between resistance determinants in human pathogens and agricultural practices. The increase of CTX-M β-lactamases in clinical settings may explain why *E. coli* gains SHR determinants. Limited data on this topic exist, but they are publicly available through an international initiative for further research [8].

5. Conclusions and Future Directions

This review covers genetic diversity, pathogenesis, resistance, and implications in *E. coli* infections. Infections are often transmitted directly among people, with high-risk activities as sources. More research is needed, including molecular typing for outbreak detection and targeted interventions. Collaboration among researchers, practitioners, and clinicians is crucial to address resistance and healthcare-associated infections. Understanding genetic diversity in *E. coli* will help mitigate risks.

References

1. Abram K, Udaondo Z, Bleker C, Wanchai V, Wassenaar TM, Robeson MS, Ussery DW. Mash-based analyses of *Escherichia coli* genomes reveal 14 distinct phylogroups. Commun Biol. 2021;4(1):117.
2. Anjum MF, Schmitt H, Börjesson S, Berendonk TU, Donner E, Stehling EG, *et al.* The potential of using E. coli as an indicator for the surveillance of antimicrobial resistance (AMR) in the environment. Curr Opin Microbiol. 2021;64:152-158.
3. Belay WY, Getachew M, Tegegne BA, Teffera ZH, Dagne A, Zeleke TK, *et al.* Mechanism of antibacterial resistance, strategies and next-generation antimicrobials to contain antimicrobial resistance: a review. Front Pharmacol. 2024;15:1444781.
4. Bendary MM, Abdel-Hamid MI, Alshareef WA, Alshareef HM, Mosbah RA, Omar NN, *et al.* Comparative analysis of human and animal E. coli: serotyping, antimicrobial resistance, and virulence gene profiling. Antibiotics (Basel). 2022;11(5):552.
5. Condamine B, Morel-Journel T, Tesson F, Royer G, Magnan M, Bernheim A, *et al.* Strain intrinsic properties and environmental constraints together shape *Escherichia coli* dynamics and diversity over a twenty-year human gut time series. bioRxiv. 2024 Feb.
6. Desvaux M, Dalmasso G, Beyrouthy R, Barnich N, Delmas J, Bonnet R. Pathogenicity factors of genomic islands in intestinal and extraintestinal *Escherichia coli*. Front Microbiol. 2020;11:2065.
7. Flament-Simon SC, Nicolas-Chanoine MH, García V, Duprilot M, Mayer N, Alonso MP, *et al.* Clonal structure, virulence factor-encoding genes and antibiotic resistance of *Escherichia coli* causing urinary tract and other extraintestinal infections in humans in Spain and France during 2016. Antibiotics (Basel). 2020;9(4):161.
8. Ghenea AE, Zlatian OM, Cristea OM, Ungureanu A, Mititelu RR, Balasoiu AT, *et al.* TEM, CTX-M, SHV genes in ESBL-producing *Escherichia coli* and Klebsiella pneumoniae isolated from clinical samples in a Romanian county hospital predominance of CTX-M-15. Antibiotics (Basel). 2022;11(4):503.
9. Higginson EE, Sayeed MA, Pereira Dias J, Shetty V, Ballal M, Srivastava SK, *et al.* Microbiome profiling of enterotoxigenic *Escherichia coli* (ETEC) carriers highlights signature differences between symptomatic and asymptomatic individuals. mBio. 2022;13(3):e00157-22.
10. Horne T, Orr VT, Hall JPJ. How do interactions between mobile genetic elements affect horizontal gene transfer? Curr Opin Microbiol. 2023;76:102324.
11. Jiang Q, Feng M, Ye C, Yu X. Effects and relevant mechanisms of non-antibiotic factors on the horizontal transfer of antibiotic resistance genes in water environments: a review. Sci Total Environ. 2022;833:155084.
12. Johansson MH, Bortolaia V, Tansirichaiya S, Aarestrup FM, Roberts AP, Petersen TN. Detection of mobile genetic elements associated with antibiotic resistance in Salmonella enterica using a newly developed web tool: MobileElementFinder. J Antimicrob Chemother. 2021;76(1):101-109.
13. Koga T, Suda K, Fujino T, Ohara S, Hamada A, Nishino M, *et al.* KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from *in vitro* experiments. J Thorac Oncol. 2021;16(8):1321-1332.
14. Li X, Hu H, Zhu Y, Wang T, Lu Y, Wang X, *et al.* Population structure and antibiotic resistance of swine extraintestinal pathogenic *Escherichia coli* from China. Nat Commun. 2024;15(1):5811.
15. Lin WH, Wang MC, Liu PY, Chen PS, Wen LL, Teng CH, Kao CY. *Escherichia coli* urinary tract infections: host age-related differences in bacterial virulence factors and antimicrobial susceptibility. J Microbiol Immunol Infect. 2022;55(2):249-256.
16. Ning Q, Wang D, An J, Ding Q, Huang Z, Zou Y, *et al.* Combined effects of nanosized polystyrene and erythromycin on bacterial growth and resistance mutations in *Escherichia coli*. J Hazard Mater. 2022;422:126858.
17. Perestrelo S, Amaro A, Brouwer MS, Clemente L, Ribeiro Duarte AS, Kaesbohrer A, *et al.* Building an international One Health strain-level database to characterise the epidemiology of AMR threats: ESBL-AmpC producing E. coli as an example challenges and perspectives. Antibiotics (Basel). 2023;12(3):552.

18. Pokharel P, Dhakal S, Dozois CM. The diversity of *Escherichia coli* pathotypes and vaccination strategies against this versatile bacterial pathogen. Microorganisms. 2023;11(5):1164.
19. Pulingam T, Parumasivam T, Gazzali AM, Sulaiman AM, Chee JY, Lakshmanan M, *et al.* Antimicrobial resistance: prevalence, economic burden, mechanisms of resistance and strategies to overcome. Eur J Pharm Sci. 2022;170:106103.
20. Qin S, Xiao W, Zhou C, Pu Q, Deng X, Lan L, *et al.* Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. Signal Transduct Target Ther. 2022;7(1):199.
21. Rodríguez-Beltrán J, DelaFuente J, Leon-Sampedro R, MacLean RC, San Millan A. Beyond horizontal gene transfer: the role of plasmids in bacterial evolution. Nat Rev Microbiol. 2021;19(6):347-359.
22. Rybak B, Krawczyk B, Furmanek-Blaszk B, Wysocka M, Fordon M, Ziolkowski P, *et al.* Antibiotic resistance, virulence, and phylogenetic analysis of *Escherichia coli* strains isolated from free-living birds in human habitats. PLoS One. 2022;17(1):e0262236.
23. Vinayamohan PG, Pellissery AJ, Venkitanarayanan K. Role of horizontal gene transfer in the dissemination of antimicrobial resistance in food animal production. Curr Opin Food Sci. 2022;47:100882.
24. Zhang F, Weckhorst JL, Assié A, Hosea C, Ayoub CA, Khodakova AS, *et al.* Natural genetic variation drives microbiome selection in the Caenorhabditis elegans gut. Curr Biol. 2021;31(12):2603-2618.
25. Zhang S, Abbas M, Rehman MU, Huang Y, Zhou R, Gong S, *et al.* Dissemination of antibiotic resistance genes (ARGs) via integrons in *Escherichia coli*: a risk to human health. Environ Pollut. 2020;266:115260.